C4X Discovery Holdings plc has outlicensed its once daily oral NRF2 (Nuclear factor-erythroid factor 2-related factor 2) activator to Astrazeneca plc in a deal with a potential value of $402 million. Of that, $2 million is being paid up front, with a further $14 million in preclinical milestones, which C4X CEO Clive Dix expects to trigger within the next two years.